The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.
 
Jodi A. Kagihara
No Relationships to Disclose
 
Bradley Corr
Consulting or Advisory Role - Genentech; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novocure (Inst); Tesaro/GSK
Research Funding - Clovis Oncology (Inst)
 
Jose Maria Pacheco
Honoraria - Genentech/Roche (Inst)
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines (Inst); Gerson Lehrman Group; Hengrui Pharmaceutical ; Jazz Pharmaceuticals; Pfizer; Takeda (Inst)
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Daiichi Sankyo/UCB Japan; Pfizer; Takeda
 
S. Lindsey Davis
Honoraria - Bristol-Myers Squibb; Incyte; OncLive
Speakers' Bureau - Allergan (I); Teva (I)
Research Funding - AstraZeneca (Inst); Boston Scientific (I); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Merck (Inst); OncoMed (Inst); Roche (Inst); Senhwa Biosciences (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - HalioDx; Ipsen (Inst); Pfizer (Inst)
Research Funding - Merck (Inst)
Other Relationship - Immune Design
 
Sunnie S. Kim
Consulting or Advisory Role - Daiichi Sankyo/Lilly
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cantargia AB (Inst); Celldex (Inst); Debiopharm Group (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); KHAR Medical (Inst); Kinex (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Roche (Inst); SQZ Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Suvica
 
Amy M. Heim
Employment - OnKure
Travel, Accommodations, Expenses - OnKure
 
John A. DeMattei
Employment - OnKure
Leadership - OnKure
Stock and Other Ownership Interests - OnKure
Research Funding - OnKure
Travel, Accommodations, Expenses - OnKure
 
Gilad Gordon
Employment - OnKure
 
Todd A. Triplett
Research Funding - OnKure (Inst)
 
S. Gail Eckhardt
Leadership - NuGenerex Immuno-Oncology (NGIO); OnKure; Syros Pharmaceuticals
Stock and Other Ownership Interests - OnKure; Suvica; Syros Pharmaceuticals
Honoraria - Guardant Health; Merck
Consulting or Advisory Role - Merck; OncoTex; OnKure; Suvica; Zai Lab
Research Funding - OnKure (Inst); Revolution Medicines (Inst)
Patents, Royalties, Other Intellectual Property - One of the scientific collaborators at CU Boulder filed for a patent for one of his drugs.
Travel, Accommodations, Expenses - Guardant Health; Merck
 
James D. Winkler
Employment - Frontier Medicines; Frontier Medicines; OnKure
Stock and Other Ownership Interests - OnKure; OnKure
 
Anthony D. Piscopio
Employment - OnKure
 
Jennifer Robinson Diamond
Consulting or Advisory Role - immunomedics
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Immunomedics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); OnKure (Inst); Rexahn Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medimmune